Cardiol Therapeutics Inc. (CRDL)
USD 0.99
(-1.56%)
USD 0.99
(-1.56%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 158.53 Thousand CAD | 606.97% |
| 2022 | 22.42 Thousand CAD | -69.23% |
| 2021 | 72.87 Thousand CAD | -30.37% |
| 2020 | 104.65 Thousand CAD | -25.4% |
| 2019 | 140.27 Thousand CAD | -47.89% |
| 2018 | 269.21 Thousand CAD | 41.66% |
| 2017 | 190.04 Thousand CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 142.55 Thousand CAD | 0.0% |
| 2024 Q1 | 150.66 Thousand CAD | 0.0% |
| 2023 Q4 | 158.53 Thousand CAD | 4.2% |
| 2023 Q2 | - CAD | -100.0% |
| 2023 Q1 | 9089.00 CAD | -59.47% |
| 2023 FY | 158.53 Thousand CAD | 606.97% |
| 2023 Q3 | 152.14 Thousand CAD | 0.0% |
| 2022 Q2 | 48.19 Thousand CAD | -20.55% |
| 2022 Q3 | 35.45 Thousand CAD | -26.43% |
| 2022 FY | 22.42 Thousand CAD | -69.23% |
| 2022 Q1 | 60.66 Thousand CAD | -16.75% |
| 2022 Q4 | 22.42 Thousand CAD | -36.75% |
| 2021 Q1 | 95.18 Thousand CAD | -9.05% |
| 2021 FY | 72.87 Thousand CAD | -30.37% |
| 2021 Q4 | 72.87 Thousand CAD | -2.27% |
| 2021 Q3 | 74.56 Thousand CAD | -12.54% |
| 2021 Q2 | 85.25 Thousand CAD | -10.43% |
| 2020 Q1 | 131.62 Thousand CAD | -6.17% |
| 2020 FY | 104.65 Thousand CAD | -25.4% |
| 2020 Q4 | 104.65 Thousand CAD | -8.06% |
| 2020 Q3 | 113.82 Thousand CAD | -7.31% |
| 2020 Q2 | 122.79 Thousand CAD | -6.71% |
| 2019 Q3 | 148.71 Thousand CAD | -3.72% |
| 2019 Q2 | 154.45 Thousand CAD | 0.0% |
| 2019 Q1 | - CAD | -100.0% |
| 2019 FY | 140.27 Thousand CAD | -47.89% |
| 2019 Q4 | 140.27 Thousand CAD | -5.67% |
| 2018 Q4 | 269.21 Thousand CAD | -97.86% |
| 2018 FY | 269.21 Thousand CAD | 41.66% |
| 2018 Q1 | - CAD | -100.0% |
| 2018 Q2 | 10.05 Million CAD | 0.0% |
| 2018 Q3 | 12.57 Million CAD | 25.13% |
| 2017 FY | 190.04 Thousand CAD | 0.0% |
| 2017 Q4 | 190.04 Thousand CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 99.968% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -35.348% |
| Embecta Corp. | 1.62 Billion USD | 99.99% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 99.969% |
| PainReform Ltd. | 30 Thousand USD | -428.44% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 70.59% |
| SCYNEXIS, Inc. | 12.15 Million USD | 98.696% |
| Journey Medical Corporation | 14.62 Million USD | 98.916% |
| Safety Shot Inc | 304.9 Thousand USD | 48.006% |
| Alpha Teknova, Inc. | 13.25 Million USD | 98.804% |
| Bright Green Corporation | 201.78 Thousand USD | 21.434% |
| Procaps Group, S.A. | 28.41 Million USD | 99.442% |
| Alvotech | 1.02 Billion USD | 99.985% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 99.949% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 99.826% |
| Cosmos Health Inc. | 3.03 Million USD | 94.777% |
| Dynavax Technologies Corporation | 252.41 Million USD | 99.937% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.968% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | 98.81% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 70.59% |
| Theratechnologies Inc. | 51.26 Million USD | 99.691% |
| Harrow Health, Inc. | 183.17 Million USD | 99.913% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -82.221% |
| Biofrontera Inc. | 804 Thousand USD | 80.282% |
| DURECT Corporation | 2.7 Million USD | 94.133% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 99.522% |
| Cronos Group Inc. | 1.55 Million USD | 89.831% |
| OptiNose, Inc. | 611 Thousand USD | 74.054% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 99.968% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 99.536% |
| RedHill Biopharma Ltd. | 455 Thousand USD | 65.158% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 99.739% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 98.76% |
| Radius Health, Inc. | 339.66 Million USD | 99.953% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | 98.455% |
| Phibro Animal Health Corporation | 458.28 Million USD | 99.965% |
| Procaps Group S.A. | 28.41 Million USD | 99.442% |
| TherapeuticsMD, Inc. | 6.53 Million USD | 97.573% |
| Viatris Inc. | 16.18 Billion USD | 99.999% |
| Rockwell Medical, Inc. | 8.29 Million USD | 98.088% |
| Aytu BioPharma, Inc. | 10.87 Million USD | 98.543% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | 52.817% |
| Tilray Brands, Inc. | 287.93 Million USD | 99.945% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 99.868% |
| Shineco, Inc. | 10.01 Million USD | 98.417% |
| PetIQ, Inc. | 437.82 Million USD | 99.964% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | 24.509% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 99.939% |
| Alimera Sciences, Inc. | 64.48 Million USD | 99.754% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | 99.588% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -17.354% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | 97.688% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | 77.982% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -605.088% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 99.516% |
| Hempacco Co., Inc. | 5.93 Million USD | 97.327% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 99.985% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 99.718% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 99.974% |
| Currenc Group, Inc. | 2.5 Million USD | 93.676% |
| Kamada Ltd. | 7.43 Million USD | 97.869% |
| Indivior PLC | 235.66 Million USD | 99.933% |
| Evoke Pharma, Inc. | 5 Million USD | 96.829% |
| Flora Growth Corp. | 942 Thousand USD | 83.171% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -605.088% |
| Evolus, Inc. | 120.35 Million USD | 99.868% |
| HUTCHMED (China) Limited | 48.18 Million USD | 99.671% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 99.973% |
| Akanda Corp. | 2.49 Million USD | 93.651% |